2020
Major Subtypes of Mature T- and NK-Cell Neoplasms
Irshaid L, Xu M. Major Subtypes of Mature T- and NK-Cell Neoplasms. Practical Anatomic Pathology 2020, 175-188. DOI: 10.1007/978-3-030-32189-5_8.Peer-Reviewed Original ResearchT-cell lymphomaNK-cell neoplasmsPeripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaCutaneous T-cell lymphomaBusy practiceAnaplastic large cell lymphomaCommon T-cellNK-cell lymphomasLarge cell lymphomaClinical workupT cellsCell lymphomaLymphomaMajor subtypesNeoplasmsMature TMolecular evaluationWorkupSubtypesIntestine
2018
Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses
Romberg N, Le Coz C, Glauzy S, Schickel JN, Trofa M, Nolan BE, Paessler M, Xu M, Lambert MP, Lakhani SA, Khokha MK, Jyonouchi S, Heimall J, Takach P, Maglione PJ, Catanzaro J, Hsu FI, Sullivan KE, Cunningham-Rundles C, Meffre E. Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal Of Allergy And Clinical Immunology 2018, 143: 258-265. PMID: 29935219, PMCID: PMC6400323, DOI: 10.1016/j.jaci.2018.06.012.Peer-Reviewed Original ResearchConceptsCommon variable immunodeficiencyVariable immunodeficiencyB cellsCommensal bacteriaIsotype-switched memory B cellsRegulatory T cell frequencyFollicular helper T cellsGC responseIsotype-switched antibodiesT cell frequenciesSubset of patientsT cell compartmentHelper T cellsPeripheral blood samplesMemory B cellsGerminal center responseB cell clonesAutoimmune cytopeniasGC hyperplasiaSerum endotoxemiaExcisional lymphAntibody responseT cellsMucosal microbiotaSomatic hypermutation frequencies
2015
Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs
Verma R, Mai Z, Xu M, Zhang L, Dhodapkar K, Dhodapkar M. Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs. Blood 2015, 126: 913. DOI: 10.1182/blood.v126.23.913.913.Peer-Reviewed Original ResearchResidual MM cellsDegradation of IKZF1MM cellsClonogenic growthRNAi-mediated inhibitionHDAC inhibitorsMyeloma cellsResidual myeloma cellsSynergistic anti-tumor effectImmune-modulatory drugsHuman MM cellsPrimary MM cellsAnti-myeloma effectTrichostatin AMM plasma cellsAnti-tumor effectsMM cell linesAnti-proliferative effectsConcurrent therapyImmunomodulatory drugsResidual diseaseModulatory drugsPlasma cellsT cellsRecent studies